Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s recent game plan. Cramer had mixed feelings about the stock, as he stated: On the other hand, I worry about Pfizer because while its stock has a terrific yield, I haven’t seen anything of late that would make me feel there’s a new blockbuster here that could move the needle. Although I was thinking about when I saw Verizon do that today, which was also a bond that turned into a stock… it maybe could happen to Pfizer. Photo by Spencer Davis on ...

Core Viewpoint - Pfizer Inc. is viewed as a stock with a good yield but lacking momentum, leading to a recommendation of a weak hold by Jim Cramer [1] Group 1: Stock Performance and Yield - Pfizer has a current yield of 6.8% to 6.9%, which is considered attractive, especially in a market where the stock has not shown significant price appreciation [1] - The stock is compared to a bond equivalent due to its stable yield, providing decent returns even if the stock price remains stagnant [1] Group 2: Future Prospects - Pfizer is expected to present more information about its pipeline and future plans at the JPMorgan conference in January 2024, which may positively influence investor sentiment [1] - The company has acquired several businesses in recent years, which could help build a robust pipeline to counteract concerns over patent expirations [1]

Core Viewpoint - Pfizer Inc. is viewed as a stock with potential growth opportunities, particularly with upcoming developments expected to be discussed at the JPMorgan conference in January 2024, while also providing a substantial dividend yield of approximately 6.8% to 6.9% [1][2]. Group 1: Company Overview - Pfizer Inc. develops and sells medicines and vaccines for various health conditions, including heart disease, infections, COVID-19, and rare diseases [2]. - The company has faced challenges with share price appreciation, leading to its characterization as a bond equivalent due to its high yield [2]. Group 2: Investment Potential - The stock is considered controversial due to its stagnant share price, but the high yield offers a decent return even if the stock does not appreciate significantly [2]. - Pfizer has the potential to leverage its recent acquisitions to build a strong pipeline that could mitigate concerns over patent expirations [2].

Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School students. A student asked if the stock, given the company’s reputation for innovation, its decline of over 50% from its peak, and recent deals involving Metsera and the Trump administration on drug pricing, is now a buy. In response, Cramer said: “No. Pfizer sells at eight times earnings and will continue to sell at eight times earnings. I’ll give you an example of what Dr. Bourla shou ...

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer had in this week’s game plan. Cramer discussed the future possibilities of the stock, as he commented: “Now, will Pfizer break out from the $25 level? Oh, it’s been a dull run for this former growth drug stock as shareholders seem to be satisfied with a 7% yield, not much price appreciation. I like growth, but that dividend seems safe, and it’s backed up by cash flow. On Tuesday morning, we’ll find out if Pfizer’s going to be more of a stock and less ...